Download PDF
Thromb Haemost 2016; 116(01): 69-77
DOI: 10.1160/TH15-12-0981
Cellular Haemostasis and Platelets
Schattauer GmbH

Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel

Insights from the ELEVATE-TIMI 56 Trial
Edward T. Carreras
1   Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USA
,
Willibald Hochholzer
2   University Heart Center Freiburg, Bad Krozingen, Department of Cardiology and Angiology II, Bad Krozingen, Germany
,
Andrew L. Frelinger III
3   Center for Platelet Research Studies, Division of Hematology/Oncology, Boston Children’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
,
Francesco Nordio
4   TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
,
Michelle L. O’Donoghue
4   TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
,
Stephen D. Wiviott
4   TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
,
Dominick J. Angiolillo
5   University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, USA
,
Alan D. Michelson
3   Center for Platelet Research Studies, Division of Hematology/Oncology, Boston Children’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
,
Marc S. Sabatine
4   TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
,
Jessica L. Mega   #
4   TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
6   Verily Life Sciences, Mountain View, California, USA
› Author Affiliations Financial support: The ELEVATE-TIMI 56 trial was funded by an investigator-initiated grant from Bristol-Myers Squibb/sanofi-aventis. Research supplies were provided by Accumetrics and Nanosphere. Dr. Mega was supported in part by grant K99/R00 HL098461 from the National Institutes of Health. Dr. Hochholzer is supported in part by the German Heart Foundation.
Further Information

Publication History

Received: 23 December 2015

Accepted after minor revision: 10 March 2016

Publication Date:
27 November 2017 (online)

    Permissions and Reprints

Summary

Both diabetes mellitus (DM) and carriage of the CYP2C19*2 allele are associated with a reduced response to clopidogrel. The relative contributions of these factors and whether higher clopidogrel doses can overcome both factors remain unknown. The objective of this study was to test the ability of clopidogrel doses up to 300 mg daily to decrease platelet reactivity in patients with DM and/or CYP2C19*2. ELEVATE-TIMI 56 randomised 333 patients with coronary artery disease to different maintenance doses of clopidogrel in four treatment periods, each lasting approximately 14 days. On-treatment platelet reactivity was compared between patients stratified by DM, CYP2C19*2 status and clopidogrel dose. Both DM and CYP2C19*2 were independently associated with elevated on-treatment platelet reactivity with clopidogrel 75 mg daily (p<0.0001 for each). With 75 mg, mean on-treatment PRU was progressively higher (p trend <0.001) when evaluating patients: with neither DM nor CYP2C19*2 (150.7; 95 % CI 140.5–162.6), with only DM (187.2; 95 % CI, 171.3–206.9), with only CYP2C19*2 (227.9; 95 % CI, 205.1–250.8), and with both DM and CYP2C19*2 (239.9; 95 % CI, 209.7–270.1). Notably, with 75 mg, patients with only CYP2C19*2 had higher ontreatment platelet reactivity than those with only DM (p=0.0068). To achieve on-treatment platelet reactivity similar to that seen with clopidogrel 75 mg in patients with neither DM nor CYP2C19*2, the following doses were required: 150 mg with only DM, 225 mg with only CYP2C19*2, and 300 mg with both DM and CYP2C19*2. Patients with both DM and CYP2C19*2 required a four-fold increase in clopidogrel maintenance dose as compared to patients without these factors to achieve a similar antiplatelet response.

Keywords

Diabetes mellitus - ischaemic heart disease - platelet pharmacology - polymorphisms

# On leave.


 

  • References

  • 1 Inzucchi SE. Diagnosis of diabetes. N Engl J Med 2013; 368: 193.
    CrossrefPubMedGoogle Scholar
  • 2 Bonello L, Tantry US, Marcucci R. et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-933.
    CrossrefPubMedGoogle Scholar
  • 3 Morel O, Kessler L, Ohlmann P. et al. Diabetes and the platelet: toward new therapeutic paradigms for diabetic atherothrombosis. Atherosclerosis 2010; 212: 367-376.
    CrossrefPubMedGoogle Scholar
  • 4 Donahoe SM, Stewart GC, McCabe CH. et al. Diabetes and mortality following acute coronary syndromes. J Am Med Assoc 2007; 298: 765-775.
    CrossrefPubMedGoogle Scholar
  • 5 Angiolillo DJ, Bernardo E, Sabate M. et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007; 50: 1541-1547.
    CrossrefPubMedGoogle Scholar
  • 6 Angiolillo DJ, Jakubowski JA, Ferreiro JL. et al. Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. J Am Coll Cardiol 2014; 64: 1005-1014.
    CrossrefPubMedGoogle Scholar
  • 7 Brar SS, ten Berg J, Marcucci R. et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011; 58: 1945-1954.
    CrossrefPubMedGoogle Scholar
  • 8 Mega JL, Close SL, Wiviott SD. et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
    CrossrefPubMedGoogle Scholar
  • 9 Mega JL, Simon T, Collet JP. et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. J Am Med Assoc 2010; 304: 1821-1830.
    CrossrefPubMedGoogle Scholar
  • 10 Shuldiner AR, O’Connell JR, Bliden KP. et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. J Am Med Assoc 2009; 302: 849-857.
    CrossrefPubMedGoogle Scholar
  • 11 Trenk D, Hochholzer W, Fromm MF. et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008; 51: 1925-1934.
    CrossrefPubMedGoogle Scholar
  • 12 Hochholzer W, Trenk D, Fromm MF. et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 2010; 55: 2427-2434.
    CrossrefPubMedGoogle Scholar
  • 13 Mega JL, Hochholzer W, Frelinger 3rd AL. et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. J Am Med Assoc 2011; 306: 2221-2228.
    PubMedGoogle Scholar
  • 14 Price MJ, Angiolillo DJ, Teirstein PS. et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 2011; 124: 1132-1137.
    CrossrefPubMedGoogle Scholar
  • 15 Angiolillo DJ, Fernandez-Ortiz A, Bernardo E. et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005; 54: 2430-2435.
    CrossrefPubMedGoogle Scholar
  • 16 Duzenli MA, Ozdemir K, Aygul N. et al. Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin. Am J Cardiol 2008; 102: 396-400.
    CrossrefPubMedGoogle Scholar
  • 17 Mangiacapra F, Patti G, Peace A. et al. Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention. Am J Cardiol 2010; 106: 619-623.
    CrossrefPubMedGoogle Scholar
  • 18 Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation 2011; 123: 798-813.
    CrossrefPubMedGoogle Scholar
  • 19 Geisler T, Anders N, Paterok M. et al. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 2007; 30: 372-374.
    CrossrefPubMedGoogle Scholar
  • 20 Serebruany V, Pokov I, Kuliczkowski W. et al. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Thromb Haemost 2008; 100: 76-82.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Erlinge D, Varenhorst C, Braun OO. et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 2008; 52: 1968-1977.
    CrossrefPubMedGoogle Scholar
  • 22 Ueno M, Ferreiro JL, Tomasello SD. et al. Functional profile of the platelet P2Y(1)(2) receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease. Thromb Haemost 2011; 105: 730-732.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Rocca B, Santilli F, Pitocco D. et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost 2012; 10: 1220-1230.
    CrossrefPubMedGoogle Scholar
  • 24 Li Y, Woo V, Bose R. Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus. Am J Physiol Heart Circ Physiol 2001; 280: H1480-1489.
    CrossrefPubMedGoogle Scholar
  • 25 Michno A, Bielarczyk H, Pawelczyk T. et al. Alterations of adenine nucleotide metabolism and function of blood platelets in patients with diabetes. Diabetes 2007; 56: 462-467.
    CrossrefPubMedGoogle Scholar
  • 26 Angiolillo DJ, Shoemaker SB, Desai B. et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007; 115: 708-716.
    CrossrefPubMedGoogle Scholar
  • 27 Wiviott SD, Braunwald E, Angiolillo DJ. et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008; 118: 1626-1636.
    CrossrefPubMedGoogle Scholar
  • 28 Angiolillo DJ, Badimon JJ, Saucedo JF. et al. A pharmacodynamic comparison of prasugrel vs high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Eur Heart J 2011; 32: 838-846.
    CrossrefPubMedGoogle Scholar
  • 29 Price MJ, Berger PB, Teirstein PS. et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. J Am Med Assoc 2011; 305: 1097-1105.
    CrossrefPubMedGoogle Scholar
  • 30 Collet JP, Cuisset T, Range G. et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012; 367: 2100-2109.
    CrossrefPubMedGoogle Scholar